Expression pattern of TMCO1 in pan-cancer and its correlation with prognosis and immune invasion

DONG Yuan; LI Jialu; WANG Yu; ZHANG Xiaoli

PDF(12230 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2023, Vol. 34 ›› Issue (9) : 771-780.

ORIGINAL ARTICLES

Expression pattern of TMCO1 in pan-cancer and its correlation with prognosis and immune invasion

DONG Yuan^1,2, LI Jialu^1,2, WANG Yu³, ZHANG Xiaoli²

Author information +

History +

Abstract

Objective To investigate the TMCO1 expression levels in pan-cancer and its correlations with prognosis and immune invasion.Methods GEPIA database and TIMER2.0 database were used to analyze the expression levels of TMCO1 in different cancer tissues and adjacent tissues, as well as correlations between TMCO1 expression and the main clinical stages. UCSC database and GEPIA database were used to analyze the prognostic value of TMCO1. Sangerbox database and TIMER2.0 were used to analyze the correlation between TMCO1 and immune cell infiltration and immune checkpoints. Finally, String and GEPIA databases were used to obtain the genes bound or co-expressed with TMCO1 in tumors for GO and KEGG enrichment analysis.Results Compared with normal tissues, the expression of TMCO1 was up-regulated in most tumors and down-regulated in a few tumors. High expression of TMCO1 was associated with poor prognosis of 6 tumors and better prognosis of 1 tumor. TMCO1 was positively correlated with neutrophil infiltration and immune checkpoint gene expression. Enrichment analysis showed that TMCO1 might be related with endoplasmic reticulum stress.Conclusions TMCO1 is a protein associated with the prognosis of various tumors, which is related with neutrophil infiltration, immune checkpoint gene expression and endoplasmic reticulum stress process, and may be a potential tumor therapeutic target in the future.

Key words

TMCO1 / pan-cancer / differential expression / endoplasmic reticulum stress / immune checkpoints

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

DONG Yuan, LI Jialu, WANG Yu, ZHANG Xiaoli. Expression pattern of TMCO1 in pan-cancer and its correlation with prognosis and immune invasion[J]. Medical Journal of the Chinese People Armed Police Forces. 2023, 34(9): 771-780

References

[1] Batchelor-Regan H, Xin B, Zhou A, et al. From disease description and gene discovery to functional cell pathway: a decade-long journey for TMCO1 [J]. Front Genet, 2021,12:652400.
[2] Pehlivan D, Karaca E, Aydin H,et al. Whole-exome sequencing links TMCO1 defect syndrome with cerebro-facio-thoracic dysplasia [J]. Eur J Hum Genet, 2014,22(9):1145-1148.
[3] Zukerman R, Harris A, Vercellin A V, et al. Molecular genetics of glaucoma: subtype and ethnicity considerations [J]. Genes (Basel), 2020,12(1):55.
[4] Zheng S, Zhao D, Hou G,et al. iASPP suppresses Gp78-mediated TMCO1 degradation to maintain Ca²⁺ homeostasis and control tumor growth and drug resistance [J]. Proc Natl Acad Sci U S A, 2022,119(6):e2111380119.
[5] Yang C, Wang Y, Bai J Q, et al. Mechanism of transmembrane and coiled-coil domain 1 in the regulation of proliferation and migration of A549 cells [J]. Oncol Lett, 2020,20(5):159.
[6] Sun Z, Zhang H, Wang X, et al. TMCO1 is essential for ovarian follicle development by regulating ER Ca²⁺ store of granulosa cells [J]. Cell Death Differ, 2018,25(9):1686-1701.
[7] Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells [J]. Nucleic Acids Res, 2020,48(W1):509-514.
[8] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res, 2017,45(W1):98-102.
[9] Danilova L, Ho W J, Zhu Q, et al.Programmed cell death ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival [J]. Cancer Immunol Res, 2019,7(6):886-895.
[10] Topalian S L, Drake C G, Pardoll D M. Immune checkpoint blockade: a common denominator approach to cancer therapy [J]. Cancer Cell, 2015,27(4):450-461.
[11] Zouein J, Kesrouani C, Kourie H R. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare [J].Immunotherapy, 2021, 13(12): 1053- 1065.
[12] Steuer C E, Ramalingam S S. Tumor mutation burden: leading immunotherapy to the era of precision medicine? [J]. Clin Oncol, 2018,36(7):631-632.
[13] Osipov A, Saung M T, Zheng L, et al. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape [J]. Immunother Cancer, 2019,7(1):224.
[14] Wang J, Jia Y,Wang N,et al. The clinical significance of tumor-infiltrating neutrophils and neutrophilto-CD8⁺ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma [J]. J Transl Med, 2014,12:7.
[15] Beyrau M, Bodkin J V, Nourshargh S. Neutrophil heterogeneity in health and disease: a revitalized avenue in inflammation and immunity [J]. Open Biol, 2012,2(11):120134.
[16] de Ke Visser S B,Wellenstein M D,de Visser K E. Neutrophils in cancer:neutral no more [J]. Nat Rev Cancer, 2016,16(7):431-446.
[17] 周金花, 蒋树龙, 王伟,等. 肿瘤相关中性粒细胞与肺癌的相关研究进展[J]. 中国肺癌杂志, 2019, 22(11):5.
[18] Hajizadeh F, Aghebati M L, Alexander M, et al. Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer[J].Life Sci, 2021, 264: 118699.
[19] Roland C L, Dineen S P, Toombs J E, et al. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts [J]. Exp Biol Med (Maywood), 2010,235(2):263-270.
[20] Zhou Z, Wang P, Sun R, et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3[J].J Immunother Cancer, 2021,9(3):e001946.
[21] Zhou S L, Zhou Z J, Hu Z Q, et al. Tumor-associated neutrophils recruit macrophages and t-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib [J].Gastroenterology, 2016,150(7):1646-1658.
[22] Mattoscio D, Isopi E, Lamolinara A, et al. Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes?[J]. Exp Clin Cancer Res, 2021,40(1):129.
[23] Sitia R, Braakman I. Quality control in the endoplasmic reticulum protein factory [J]. Nature, 2003,426: 891-894.
[24] Obacz J, Avril T, Rubio-Patiño C, et al. Regulation of tumor-stroma interactions by the unfolded protein response [J]. FEBS J, 2019,286(2):279-296.
[25] Wang Q C, Zheng Q, Tan H, et al. TMCO1 is an ER Ca²⁺ load-activated Ca²⁺ channel [J]. Cell, 2016,165(6):1454-1466.
[26] Usui M, Yamaguchi S, Tanji Y , et al. Atf6α-null mice are glucose intolerant due to pancreatic β-cell failure on a high-fat diet but partially resistant to diet-induced insulin resistance [J]. Metabolism, 2012,61: 1118-1128.
[27] Zhou Y, Shu F, Liang X, et al. Ampelopsin induces cell growth inhibition and apoptosis in breast cancer cells through ROS generation and endoplasmic reticulum stress pathway [J]. PLoS One, 2014,9(2):e89021.
[28] Zulkifli A, Tan F H, Areeb Z, et al. Carfilzomib promotes the unfolded protein response and apoptosis in cetuximab-resistant colorectal cancer [J]. Int J Mol Sci, 2021,22(13):7114.
[29] Zhang X, Wang J, Zhuang J,et al. A Novel glycolysis-related four-mRNA signature for predicting the survival of patients with breast cancer [J]. Front Genet, 2021,12:606937.
[30] Zimmermann R, Lang S, Lerner M, et al. Quantitative proteomics and differential protein abundance analysis after the depletion of PEX3 from human cells identifies additional aspects of protein targeting to the ER [J]. Int J Mol Sci, 2021,22(23):13028.
[31] Li J, Liu C, Li Y, et al. TMCO1-mediated Ca²⁺ leak underlies osteoblast functions via CaMKII signaling [J]. Nat Commun, 2019,10(1):1589.